ID   HCC1428-LTED
AC   CVCL_YX83
SY   HCC1428 LTED; HCC1428-Long Term Estrogen-Deprived
DR   Wikidata; Q93982296
RX   PubMed=26116361;
CC   Population: Caucasian.
CC   Characteristics: Derived from parent cell line by long-term culture in the presence of RPMI-1640 medium containing 10% dextran charcoal stripped serum (DCC) (PubMed=26116361).
CC   Sequence variation: Gene fusion; HGNC; 73; ABCG1 + HGNC; 11024; SLC37A1; Name(s)=SLC37A1-ABCG1 (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 3701; FHIT; Unexplicit; Ex4del; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C5214; Breast adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1252 ! HCC1428
SX   Female
AG   49Y
CA   Cancer cell line
DT   Created: 12-03-20; Last updated: 29-06-23; Version: 10
//
RX   PubMed=26116361; DOI=10.1158/1535-7163.MCT-15-0143;
RA   Ribas R., Pancholi S., Guest S.K., Marangoni E., Gao Q., Thuleau A.,
RA   Simigdala N., Polanska U.M., Campbell H., Rani A., Liccardi G.,
RA   Johnston S.R.D., Davies B.R., Dowsett M., Martin L.-A.;
RT   "AKT antagonist AZD5363 influences estrogen receptor function in
RT   endocrine-resistant breast cancer and synergizes with fulvestrant
RT   (ICI182780) in vivo.";
RL   Mol. Cancer Ther. 14:2035-2048(2015).
//